Press Releases and Blog
Blog
Correcting the Record: Pharmacy Benefit Companies Support and Promote Generics and Biosimilars
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed
Experts Urge Lawmakers to Reject “Delinking” and Other Proposed Policies That Will Increase Prescription Drug Costs
In case you missed it, Ike Brannon, senior fellow at the Jack Kemp Foundation and former senior economist for the United States Treasury and U.S.
House Hearing Underscores Misguided Proposals Targeting Pharmacy Benefit Companies Will Increase Drug Prices and Play Into Big Pharma’s Self-Serving Agenda
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy
ICYMI: Economic Experts Explain the Misunderstood Role of Pharmacy Benefit Managers
Ike Brannon, former senior economist for the United States Treasury and U.S. Congress, and Anthony Lo Sasso, professor of economics at DePaul University, explain the
Just the Facts: Research and Analysis Finds Anti-PBM Legislation Does Not Lower Prescription Drug Costs for Patients
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re
Senator Rand Paul Sounds the Alarm on Legislation Targeting Pharmacy Benefits that will Actually Increase Prescription Drug Prices
As Congress reviews legislation targeting Americans’ pharmacy benefits, Members of Congress are raising concerns about the unintended risks of significantly increasing drug costs. In case
Press Releases
New PCMA Podcast Highlights Importance of Prescription Drug Rebates
(Washington, D.C.) — The Pharmaceutical Care Management Association’s (PCMA) podcast, The Pharmacy Benefit, released a new episode, “Understanding Prescription Drug Rebates.” The podcast episode, hosted by
New Data Reveal a Stable Independent Pharmacy Market
(Washington, D.C.) — New data from the National Council for Prescription Drug Programs (NCPDP) database, highlighted today by the Pharmaceutical Care Management Association (PCMA), shows that the
Congressional Budget Office Confirms The Insulin Act Increases Health Care Costs
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released the following statement on the Congressional Budget Office’s (CBO) estimate that The INSULIN Act
Groundbreaking Research Highlights Invaluable Role of Pharmacy Benefit Managers
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on a new research paper, “The Value of Pharmacy Benefit Management”
PCMA Applauds Biden Administration Action to Stop Drug Manufacturer Patent Abuses, Lower Prescription Drug Costs
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Biden Administration’s announcement to curb drug
PCMA Statement on “The Pharmacy Benefit Manager Transparency Act”
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on today’s vote in the Commerce Committee on
94 Percent Of The Drug Dollar Is Retained By Drug Manufacturers, Drug Wholesalers, And Pharmacies
A simple fact is often lost in the din of the current drug pricing debate going on in Washington D.C. and around the country: Drug
Big Pharma’s Pay-For-Delay Keeps More Affordable Options From Entering The Market, Keeping Drug Prices High
In case you missed it, a new article in The Atlantic explains how big drug companies commonly use an anti-competitive tactic, “pay-for-delay,” to prevent more affordable options from entering the marketplace.
Drug Companies Possess Complete Autonomy On List Prices
The evidence is clear: prescription drug rebates negotiated by pharmacy benefit companies with drug companies are not correlated with drug list prices, which are set
PCMA President And CEO Explains Critical Value Of Pharmacy Benefit Companies On Capitol Hill
In case you missed it, PCMA President and CEO JC Scott testified before the U.S. House Education and the Workforce Committee Subcommittee on Health, Employment, Labor,
Business Groups and Employers Express Support for Preserving Their Contracting Flexibility
In case you missed it, business groups and individual employers from across the country signed the below letter to Congress expressing support for preserving their
Bank Of America Survey Confirms Pharmacy Benefit Market Is Competitive, Transparent, And Delivering Value For Employers
Bank of America (BofA) recently released the findings of an employer survey that found that the pharmacy benefit marketplace is highly competitive, confirmed that surveyed
Employers Hire Pharmacy Benefit Companies To Manage Growing Rx Drug Costs
Fact: Employers are under no obligation to hire pharmacy benefit companies, but a vast majority of employers work with pharmacy benefit companies. Recent findings from
New PCMA Rx Research Corner Blog: A World Without PBMs: A Lesson From Economics
In case you missed it, the Pharmaceutical Care Management Association (PCMA) released a new Rx Research Corner blog, by Vice President of Research Amanda Frost,
ICYMI: Prescription Prices Should Be Addressed At BIO International Convention
In case you missed it, Katie Payne, senior vice president for strategic communications for the Pharmaceutical Care Management Association (PCMA), discusses how the BIO International
Webinar Highlights Big Pharma’s Rising Launch Prices and Cost-Saving Value of Pharmacy Benefit Companies
Last month, the IQVIA Institute held a webinar, “The Use of Medicines in the U.S. 2023.” Panelists highlighted how big drug companies set the price of